Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine

Archives of Disease in Childhood
Petra ZimmermannNigel Curtis

Abstract

Despite immunisation, antibiotics and intensive care management, infection with Streptococcus pneumoniae remains a major cause of morbidity and mortality in children. The WHO currently recommends vaccinating infants with either a 3+0 schedule (6 weeks, 3-4 and 4-6 months of age) or 2+1 schedule (2 doses before 6 months of age, plus a booster dose at 9-15 months of age). This study investigated pneumococcal antibody responses, including persistence of antibodies, after immunisation of healthy infants with a 3+0 schedule. We measured pneumococcal antibody concentrations to all 13 antigens included in the 13-valent pneumococcal conjugate vaccine (PCV13) after immunisation with a 3+0 schedule in 91 infants at 7 months and in 311 infants at 13 months of age. The geometric mean concentrations (GMCs) and the proportion of infants with an antibody concentration above the standard threshold correlate of protection (seroprotection rate) were calculated at both time points. At 7 months of age, GMCs varied between 0.52 µg/mLand 11.52 µg/mL, and seroprotection rates varied between 69% and 100%. At 13 months of age, GMCs had decreased to between 0.22 µg/mLand 3.09 µg/mL, with the lowest responses against serotype 4, followed by 19A, 3, 6B an...Continue Reading

References

Feb 15, 2001·The New England Journal of Medicine·J EskolaUNKNOWN Finnish Otitis Media Study Group
Oct 3, 2003·The New England Journal of Medicine·Keith P KlugmanUNKNOWN Vaccine Trialists Group
Jul 14, 2009·European Journal of Dermatology : EJD·Pía López-JornetMayra Lucero Berdugo
Aug 25, 2009·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Daniel J IsaacmanRalf R Reinert
Sep 15, 2009·Lancet·Katherine L O'BrienUNKNOWN Hib and Pneumococcal Global Burden of Disease Study Team
Feb 27, 2013·Pediatrics·Allan S LieberthalDavid E Tunkel
Dec 10, 2013·Canadian Journal of Microbiology·Walter H B DemczukUNKNOWN Canadian Public Health Laboratory Network
Dec 18, 2013·The Pediatric Infectious Disease Journal·Maria Deloria KnollKatherine L O'Brien
Dec 18, 2013·The Pediatric Infectious Disease Journal·Jennifer D LooCynthia G Whitney
Dec 18, 2013·The Pediatric Infectious Disease Journal·Katherine E Fleming-DutraKatherine L O'Brien
Oct 18, 2014·The European Respiratory Journal·Sarah BrowallBirgitta Henriques-Normark
Jan 27, 2015·The Pediatric Infectious Disease Journal·Lindsay R GrantKatherine L O'Brien
Sep 17, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Shamez N LadhaniElizabeth Miller
Oct 16, 2015·BMC Infectious Diseases·Myint Tin Tin HtarHeinz-Josef Schmitt
Feb 13, 2016·The Journal of Infection·Imma GrauRoman Pallares
Dec 18, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sanjay JayasinghePeter McIntyre
Feb 23, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sanjay JayasinghePeter McIntyre
Jun 19, 2018·Emerging Infectious Diseases·Catarina Silva-CostaUNKNOWN Portuguese Study Group of Invasive Pneumococcal Disease of the Pediatric Infectious Disease Society
Sep 14, 2019·EClinicalMedicine·Petra ZimmermannNigel Curtis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.